Navigation Links
Lamictal as add-on therapy for children with epilepsy

The U.S. Food and Drug Administration has approved GlaxoSmithKline's new drug Lamictal (lamotrigine) as an addition for children whose partial seizures are inadequately controlled on their existing therapy. This new indication is an expansion of the //already-approved indications for adjunctive use in adults with partial seizures, and for the generalized seizures of Lennox-Gastaut Syndrome in children two years of age and older.

Partial seizures are the most common type of epilepsy and they begin with abnormal electrical activity in a particular location in the brain. The effect of these seizures include lip smacking, a dazed state or jerking movements of certain body parts.

The approval of the drug was based on a clinical study that demonstrated the efficacy of the drug as add-on therapy in pediatric patients who were still having frequent partial seizures (at least four per month) despite optimal doses of other anti-epilepsy drugs (AEDs). The study was a 18 week placebo controlled study in which 200 patients aged between 2 and 15 years, who were still having frequent seizures despite use of other AEDs, were randomized to treatment with Lamictal or placebo added to their current AED regimen of up to two drugs (Lamictal: 99, placebo: 101). The results showed significant reductions in the frequency of all partial seizures in children and adolescents with epilepsy when Lamictal was added to their AED regimen.

Michael Duchowny, director of the Comprehensive Epilepsy Program at Miami Children's Hospital said that Lamictal would be a welcome addition as FDA-approved therapies for children with epilepsy are limited and any clinically proven medication which can effectively control seizures in children would be an important new option to manage this condition.


'"/>




Page: 1

Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. Analysis Shows Lamictal As An Effective Additional Therapy For Treatment of Grand Mal Seizures
3. FDA Decision Encourages Lamictal Generics
4. Acupuncture May Help Chemotherapy Side Effects
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. Distraction therapy found very effective in postoperative patients
7. Acupuncture superseeds massage therapy for short term relief of pain
8. Ovarian cancer in relationship with Hormone therapy
9. New therapy better at increasing bone density
10. Gene therapy - Aim to improve blood flow
11. Gene therapy restores sight
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: